Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774446 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
A Phase 2 study of Cushing Disease, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03774446 is a Phase 2 study of Cushing Disease that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 13 participants, below the 391-participant average among 8 other Cushing Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03774446, a Phase 2 study of Cushing Disease, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
Conditions Studied
Interventions
- DRUG Seliciclib
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774446
The ClinicalTrials.gov registry entry for NCT03774446 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 391-participant average among 8 other Cushing Disease trials with a reported enrollment target (97% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cushing Disease appearing as the primary indexed condition, and to 1 intervention - of which Seliciclib is the first listed.
NCT03774446 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03774446 about?
NCT03774446 is a clinical study titled "Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease". This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
What is the current status of trial NCT03774446?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-11-02. Estimated completion is 2026-08.
What conditions does trial NCT03774446 study?
This clinical trial studies the following conditions: Cushing Disease.
What interventions are being tested in trial NCT03774446?
The interventions under investigation include: Seliciclib (DRUG).
Who is sponsoring clinical trial NCT03774446?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774446 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
RECRUITING · Phase 2
-
Safety and Efficacy of LCI699 in Cushing's Disease Patients
COMPLETED · Phase 2
-
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
RECRUITING
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.